Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Kantarjian, Hagop M.
Xiao, Lianchun
Ning, Jing
Alvarado, Yesid
Borthakur, Gautam
Daver, Naval
DiNardo, Courtney D.
Jabbour, Elias
Bose, Prithviraj http://orcid.org/0000-0002-4343-5712
Jain, Nitin
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
Naqvi, Kiran
Pemmaraju, Naveen
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Verstovsek, Srdan
Andreeff, Micheal
Kornblau, Steven M. http://orcid.org/0000-0002-5990-9548
Estrov, Zeev
Ferrajoli, Alessandra
Garcia-Manero, Guillermo
Ohanian, Maro
Wierda, William G.
Ravandi, Farhad
Cortes, Jorge E. http://orcid.org/0000-0002-8636-1071
Funding for this research was provided by:
Jazz Pharmaceuticals
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI Grant P30 CA016672)
Article History
Received: 29 January 2020
Revised: 1 June 2020
Accepted: 5 June 2020
First Online: 16 June 2020
Compliance with ethical standards
:
: GCI received research funding from Celgene and served on an advisory board for Novartis. HMK received research funding from Ariad; Astex; Bristol-Myers Squibb; Cyclacel; Daiichi-Sankyo; Pfizer; Immunogen; Jazz; Novartis and honoraria from Pfizer; Immunogen; Actinium and Takeda. YA received research funding from Jazz and honoraria from Abbott. GB received research funding from AbbVie; Incyte; Janssen; Cyclacel; BioLine Rx; NKarta: and consulting honoraria from BioLine Rx; NKarta; PTC Therapeutics; Oncoceutics, Inc. ND received research funding from Sunesis Pharmaceuticals, Inc.; Karyopharm; Immunogen; Pfizer; Incyte; Bristol-Myers Squibb; Daiichi-Sankyo; Kiromic and consulting honoraria from Sunesis Pharmaceuticals, Inc.; Karyopharm; Pfizer; Incyte; Bristol-Myers Squibb; Novartis; Otsuka America Pharmaceutical, Inc. CDD received research funding from Agios; Novartis; Celgene; Daiichi-Sankyo; Calithera Biosciences and consulting honoraria from AbbVie; Agios; Novartis; Celgene; Daiichi-Sankyo; Jazz; Notable Laboratories and is a Scientific Advisory Board member of Notable Laboratories. PB received research funding from Incyte; Celgene; CTI BioPharma; Blueprint Medicines; Constellation Pharmaceuticals; Kartos Therapeutics; Astellas; Pfizer; NS Pharma; Promedior and consulting honoraria from Incyte; Celgene; CTI BioPharma; Blueprint Medicines; Kartos Therapeutics. NJ received research funding and consulting honoraria from AbbVie; Pharmacyclics; Genentech; Bristol-Myers Squibb; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive. NP received research funding from Stemline; Novartis; Abbvie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix; and received consulting honoraria from Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Di, LFB. KT received research funding from Onconova; MEI, served on an advisory board for Symbio Pharmaceuticals; GSK; Celgene and received honoraria from Dava Oncology; Kyowa Hakko Kirin. MA received research funding from Daiichi Sankyo, Inc.; Jazz; and consultancy honoraria from Jazz; Celgene; Amgen; AstaZeneca; Dimensions Capital; and equity ownership from Reata; Aptose; Europics; Senti Bio; Oncoceutics; Oncolyze. FR received research funding from Amgen, Bristol-Myers Squibb, Merck, Seattle Genetics, Sunesis Pharmaceuticals; Pfizer; and honoraria for consulting or advisory role for Jazz; Amgen; Seattle Genetics; Sunesis Pharmaceuticals. JEC received research funding (to the institution while at the MD Anderson) and consulting honoraria from Celator/Jazz, Novartis, Daiichi, Astellas, Daiichi, Merus, Immunogen, Biopath Holdings.